|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15.05.26 - 14:03
|
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 (Business Wire)
|
|
|
Product Development Highlights:
Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial
Reported additional preclinical data for EB-003 demonstrating dual Gq and β-arrestin signaling at 5-HT2A, pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects
Corporate and Business Development Highlights:
Strengthened intellectual property portfolio with new patent issuances and allowances across EVM301 and EVM401 series
Announced the withdrawal by AbbVie, Inc. of the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric's issued U.S. Patent No. 12,138,276, which appears relevant to the bretisilocin molecule (GM-2505) acquired by AbbVie, Inc.
Presented at and Participated in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Com...
|
|
|
15.05.26 - 08:51
|
AbbVie Aktie: Enormes Potenzial dank Mega-Pipeline (Aktiencheck)
|
|
|
Minneapolis (www.aktiencheck.de) - AbbVie-Aktienanalyse von Piper Sandler:
Piper Sandler habe das Kursziel für die Aktie von AbbVie Inc. (ISIN: US00287Y1091, WKN: A1J84E, Ticker-Symbol: 4AB, NYSE-Symbol: ABBV) von 294 auf 298 USD angehoben und das Rating "overweight" beibehalten. Im Mittelpunkt des starken Investoreninteresses stehe weiterhin die Pipeline des Unternehmens im Bereich entzündlicher Darmerkrankungen (IBD). [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.05.26 - 14:06
|
Timothy P. Walbert Joins Patient Square Capital as a Senior Advisor (Business Wire)
|
|
|
MENLO PARK, Calif.--(BUSINESS WIRE)--Patient Square Capital, a leading health care investment firm, today announced that Timothy P. Walbert has joined the firm as a Senior Advisor.
Mr. Walbert brings more than three decades of biopharmaceutical leadership experience and currently serves as Managing Partner of HRZN Partners LLC and a Senior Advisor to Amgen. Most recently, he was Chairman, President, and Chief Executive Officer of Horizon Therapeutics, which he grew to approximately $4 billion in annual sales prior to its $28.3 billion acquisition by Amgen in 2023; earlier, he led IDM Pharma Inc. through its acquisition by Takeda and held senior roles at Abbott (now AbbVie), where he led the global launch of HUMIRA®, as well as at G.D. Searle & Company, Merck & Co., and Wyeth.
“Patient Square Capital has built a highly differentiated platform and a strong record of partnering with management teams to create enduring value in health care,” said Tim Walbert. “I'm pleased to join the firm as a Senior ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
